UCSF-Harvard Team Reports Encouraging Results In Drug Study Of Mice With Cancer

Researchers report that four drugs thought to disrupt the formation of blood vessels that fuel tumor growth have been shown for the first time to be effective at treating spontaneous tumors at distinct stages of progression in mice.

The study, reported in the April 30 issue of Science, provides evidence that these drugs, so-called angiogenesis inhibitors, can act against tumors in a mouse model that more closely resembles the conditions of human tumor development than the models previously used.

It also provides the first indication that the drugs vary in their efficacy depending on the stage of cancer targeted - drugs showed encouraging results when used to treat distinct stages of tumor development, including premalignancy. The model could therefore provide a platform for exploring the potential of perhaps even more effective angiogenesis inhibitors, or combinations of inhibitors, not just for the treatment of cancer, but for prevention, the researchers said.

"We've shown that these drugs have beneficial effects when used to treat mice developing organ-specific cancer in which tumors arise from premalignant lesions in their natural tissue microenvironment, representing an important extension of the evidence for efficacy of angiogenesis inhibition in cancer," said the senior author of the study, Douglas Hanahan, Ph.D., a professor of biochemistry at UCSF.

Many angiogenesis inhibitors are currently being investigated in laboratories around the world. If the results continue to be encouraging, said the lead author of the study, Gabriele Bergers, Ph.D., a visiting postdoctoral fellow in the Department of Biochemistry and Biophysics, and the Hormone Research Institute at UC San Francisco, "the strategy will be to determine which anti-angiogenesis compounds are most effective at which stage of cancer in mouse models, and to develop dosing regimens that are fine-tuned to target these specific stages of disease progression."

The ultimate question,

Contact: Jennifer O'Brien
University of California - San Francisco

Page: 1 2 3 4

Related medicine news :

1. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
2. Melanoma Patients Sentinel Lymph Nodes (SLNS) Play A Strong Role In Disease Prognosis, UCSF Study Reports
3. Irritable Bowel Syndrome The Focus Of Three UNC-CH Reports At Digestive Diseases Conference
4. Bone Marrow With Heart And Lung Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
5. Bone Marrow With Organ Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
6. BioNumerik Reports Data On Two Novel Supercomputer Engineered Anticancer Agents At 90th Annual Meeting Of The AACR
7. Changes In Levels Of LDLc From Pre- To Post-Menopausal Years Not Valuable Indicator Of Heart Disease, Reports University Of Pittsburgh Researcher
8. Medicare Policy Contradicts Preferred Treatment For Precancerous Skin Conditions, Westwood Squibb Center For Dermatology Research Reports
9. BioNumerik Reports The Supercomputer Supported Discovery Of New, Non-Toxic Chemotherapy Protecting Agent
10. International Study Finds Statins Raise Good Cholesterol, Wake Forest Physician Reports
11. ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting

Post Your Comments:

(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: ... data solutions, today announced that its MyDario product is expected to appear ... listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The ... ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/22/2017)... ROCKVILLE, Md. , Sept. 22, 2017  As ... by Republican Senators Bill Cassidy (R-LA) and ... Kalorama Information notes that the medical device industry is ... the medical device tax, the 2.3% excise tax on ... Act.  But they also want covered patients, increased visits ...
Breaking Medicine Technology:
Cached News: